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Abstract
Background: Ursolic acid (UA), a natural pentacyclic triterpenoid, exerts anti-tumor effects in various cancer types
including hepatocellular carcinoma (HCC). However, the molecular mechanisms underlying this remain largely unknown.
Methods: Cell viability and cell cycle were examined by MTT and Flow cytometry assays. Western blot analysis
was performed to measure the phosphorylation and protein expression of p38 MAPK, insulin-like growth factor
(IGF) binding protein 1 (IGFBP1) and forkhead box O3A (FOXO3a). Quantitative real-time PCR (qRT-PCR) was used
to examine the mRNA levels of IGFBP1 gene. Small interfering RNAs (siRNAs) method was used to knockdown IGFBP1
gene. Exogenous expressions of IGFBP1 and FOXO3a were carried out by transient transfection assays. IGFBP1
promoter activity was measured by Secrete-Pair™ Dual Luminescence Assay Kit. In vivo nude mice xenograft
model and bioluminescent imaging system were used to confirm the findings in vitro.
Results: We showed that UA stimulated phosphorylation of p38 MAPK. In addition, UA increased the protein,
mRNA levels, and promoter activity of IGFBP1, which was abrogated by the specific inhibitor of p38 MAPK
(SB203580). Intriguingly, we showed that UA increased the expression of FOXO3a and that overexpressed
FOXO3a enhanced phosphorylation of p38 MAPK, all of which were not observed in cells silencing of
endogenous IGFBP1 gene. Moreover, exogenous expressed IGFBP1 strengthened UA-induced phosphorylation of p38
MAPK and FOXO3a protein expression, and more importantly, restored the effect of UA-inhibited growth in cells
silencing of endogenous IGFBP1 gene. Consistent with these, UA suppressed tumor growth and increased
phosphorylation of p38 MAPK, protein expressions of IGFBP1 and FOXO3a in vivo.
Conclusion: Collectively, our results show that UA inhibits growth of HCC cells through p38 MAPK-mediated induction
of IGFBP1 and FOXO3a expression. The interactions between IGFBP1 and FOXO3a, and feedback regulatory loop of p38
MAPK by IGFBP1 and FOXO3a resulting in reciprocal pathways, contribute to the overall effects of UA. This in vitro and in
vivo study corroborates a potential novel mechanism by which UA controls HCC growth and implies that the rational
targeting IGFBP1 and FOXO3a can be potential for the therapeutic strategy against HCC.
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Background
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related deaths globally characterized by
high malignancy, aggressive progression, clinical diffi-
culty and limited therapeutic options, resulting in poor
prognosis and remaining a significant clinical challenge
[1–4]. Usually, HCC shows high mortality even after
treatments, such as chemotherapy and surgical resec-
tion, microwave ablation, trans-arterial chemoemboliza-
tion, targeted therapy and liver transplantation [5].
Furthermore, the management of patients with HCC is
complex due to the complicated molecular pathogenesis,
incurable advanced stages, and adverse responses from
available anti-HCC drugs [6, 7]. Thus, it is necessary to
develop new effective therapeutic strategies to improve
the quality of life and survival of patients with HCC. There
is currently increasing interest in Traditional Chinese
Medicine (TCM) herbal mixtures and its components,
which have been used to treat malignant tumors including
HCC with potentially beneficial outcomes [8–10]. How-
ever, the detailed mechanisms by which TCM and ex-
tracted components suppress growth of cancers including
HCC hitherto remain to be understood.
Ursolic acid (UA), a natural pentacyclic triterpenoid
carboxylic acid obtained from TCM herbs and edible
plants, exhibits potential anticancer effects through mul-
tiple mechanisms in various human cancers including
HCC [10–14]. Our previous studies have showed that UA
inhibited growth of HCC cells through AMP-activated
protein kinase alpha (AMPKα)-mediated inhibition of
transcription factor Sp1 and epigenetic regulator DNA
(cytosine-5-)-methyltransferase 1 (DNMT1) [10]. Others
found that ursolic acid induced apoptosis in HepG2 HCC
cells via activation/phosphorylation of AMPK and glyco-
gen synthase kinase 3 beta (GSK3β) [15]. However, the
precise mechanisms of UA in the control of HCC growth
remain to be determined.
Insulin-like growth factor (IGF) binding protein 1
(IGFBP1), a pivotal protein of the IGF system, has
been shown to be implicated in many cellular func-
tions including proliferation, development, apoptosis,
DNA damage repair, and tumor growth through IGF-
dependent and -independent mechanisms [16–18].
Early report showed that inhibition of IGF receptor 1
function by IGFBP1 inhibited breast cancer cell
growth [19]. Metformin, an activator of AMPK, a
central metabolic regulator, was found to increase
IGFBP1 expression, thereby inhibiting endometrial
cancer cell proliferation [20]. The role of IGFBP1 in
HCC has been reported, demonstrating that IGFBP1
inhibited the invasion and metastasis of HCC cells,
and this could be considered as an important marker
for the prognosis of HCC [21, 22]. Nevertheless, the
insight true role of IGFBP1 in cancer cell biology,
especially in growth and progression of HCC, still re-
mains controversial.
Human forkhead box class O (FOXO) transcription
factors implicated in a wide variety of cellular activities,
such as differentiation, cell cycle, metabolism, stress
resistance, mitogenic signaling, and tumor suppression
[23]. Among four members (FOXO1, FOXO3a, FOXO4,
and FOXO6), FOXO3a has been shown as a critical pro-
tein involving in proliferation, cell cycle arrest, apoptosis,
differentiation, and metabolism [24–27]. FOXO3a acted
as tumor suppressors and reduced expression of
FOXO3a was associated with poor prognosis in gastric
cancer patients [28]. On the contrary, exogenous expres-
sion of FOXO3a suppressed cancer cell growth through
regulating downstream signaling molecules [25, 26, 29].
These results indicated a tumor suppressor role of
FOXO3a, which could be a potential target for the treat-
ment of cancers.
In this study, we further explore the potential mechanism
by which UA controls growth of HCC cells. Our results in
vitro and in vivo indicated that UA inhibited growth of
HCC cells through p38 mitogen-activated protein kinase
(MAPK)-mediated induction of IGFBP1 and FOXO3a
expressions.
Methods
Reagents and cell culture
Monoclonal antibodies specific for total p38 MAPK and
the phosphor-form (Thr180/Tyr182) were purchased from
Cell Signaling Technology Inc. (Beverly, MA, USA). The
IGFBP1 and FOXO3a antibodies were obtained from Epi-
tomics (Burlingame, CA, USA). SB203580 was purchased
from Merck Millipore (Darmstadt, Germany). MTT
powder was purchased from Sigma Aldrich (St. Louis,
MO, USA). Ursolic acid was purchased from Chengdu
Must Bio-technology Company (Chengdu, Sichuan, China).
Lipofectamine 3000 reagent was purchased from Invitrogen
(Carlsbad, CA, USA). The drugs were freshly diluted to the
final concentration in culture medium before experi-
ment. Human HCC cell lines HepG2, Bel-7402, QGY-
7703, HMCC97L and HMCC97H were obtained from
the Cell Line Bank at the Laboratory Animal Center of
Sun Yat-sen University (Guangzhou, China) and the
Chinese Academy of Sciences Cell Bank of Type Culture
Collection (Shanghai, China). The cells were cultured
at 37 °C in a humidified atmosphere containing 5 %
CO2. The culture medium consisted of RPMI1640
medium (GIBCO, Shanghai, China) supplemented with
10 % (v/v) heat-inactivated fetal bovine serum (Thermo
Fisher Scientific Inc, MA, USA), 100 μg/ml streptomycin
and 100 U/mL penicillin. When cells reached 70 % con-
fluence, they were digested with 0.25 % trypsin for the
following experiments.
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Cell viability assay
Cell viability was measured using the 3-(4, 5-dimethylthia-
zol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay
and described previously [26, 30]. Briefly, HCC cells were
harvested and seeded into a 96-well microtiterplate. The
cells (5 × 103 cells/well) were treated with increasing con-
centrations of UA for up to 72 h. After incubation, 10
μL MTT solution (5 g/L) was added to each well and
HCC cells were incubated at 37 °C for an additional 4
h. Supernatant was removed, then 100 μL solvent di-
methyl sulfoxide (DMSO) was added to each well and
oscillated for 5 min. Absorbance at 570 nm was deter-
mined by ELISA reader (Perkin Elmer, Victor X5,
Waltham, MA, USA). Cell viability (% of control) was
calculated as (absorbance of test sample/absorbance of
control) × 100 %.
Cell cycle analysis
This procedure was reported previously [31]. In brief,
HCC cells were cultured in 6-well plates and treated
with increased doses of UA for 24 h. Afterwards, the
cells were harvested, and resuspended in 500 μL of cold
PBS for 2 h at 4 °C. Following washes, the fixed cells were
incubated in 1 mL of 0.1 % sodium citrate containing pro-
pidium iodide (PI) 0.05 mg and 50 μg RNase for 30 min at
room temperature (RT), subjected to FACSCalibur flow
cytometric analysis (FC500, Beckman Coulter, FL, USA).
The proportion of cells within the G0/G1, S and G2/M
phases was analyzed using the MultiCycle AV DNA
Analysis software (Phoenix Flow Systems).
Treatment with FOXO3a and IGFBP1 siRNAs
The detailed procedure was reported previously [26]. For
the transfection procedure, cells were seeded in 6-well or
96-well culture plates in RPMI 1640 medium containing
10 % FBS (no antibodies), grown to 60 % confluence, and
FOXO3a, IGFBP1 and control siRNAs (up to 50 nM) pur-
chased from Life Technologies (Carlsbad, CA, USA) were
transfected using the Lipofectamine RNAiMAX Transfec-
tion Reagent (Grand Island, NY, USA) according to the
manufacturer’s instructions. After culturing for up to 24 h,
the cells were washed and resuspended in fresh media in
the presence or absence of UA for an additional 24 h for
all other experiments.
Transient transfection assays
The detailed procedure was reported previously [32]. In
brief, HCC cells were seeded at a density of 5 x105 cells/
well in 6-well dishes and grown to 60 % confluence. For
each well, 2 μg of the desired N1-GFP or FOXO3a-GFP
plasmid DNA, kindly provided by Frank M. J. Jacobs
(Rudolf Magnus Institute of Neuroscience, Department of
Pharmacology and Anatomy, University Medical Center,
Utrecht, Netherlands) and was reported previously [33]
and the control (pCMV-6) or IGFBP1 expression vectors
(IGFBP1-pCMV6) purchased from OriGene Technolo-
gies, Inc. (Rockville, MD, USA) at a final concentration
of 2 μg/mL were transfected into the cells using the li-
pofectamine 3000 reagent according to the manufac-
turer’s instructions for up to 24 h, followed by treating
with UA for an additional 24 h. In separated experi-
ment, cell were transfected with pEZX-PG04-IGFBP1
promoter construct linked Gaussia luciferase (GLuc)
gene and secreted alkaline phosphatase (SEAP) internal
control obtained from GeneCopoeia, Inc. (GeneCopoeia,
Inc., Rockville, MD, USA). The preparation of cell extracts
and measurement of luciferase activities were deter-
mined using the Secrete-Pair Dual Luminescence Assay
Kit (GeneCopoeia, Inc., Rockville, MD, USA). Gaussia
luciferase activity was normalized with SEAP within
each sample.
Quantitative real-time PCR
A quantitative real-time PCR (qRT-PCR) assay was used
to detect IGFBP1. The primers used in this study were de-
signed as follows: IGFBP1 forward 5′- TCACAGCAGAC
AGTGTGAGAC −3′; reverse 5′- CCCAGGGATCCT
CTTCCCAT −3′; GAPDH forward 5′- AAGCCTGCCG
GTGACTAAC −3′; reverse 5′- GCGCCCAATACGACC
AAATC −3′. In brief, qRT-PCR was performed in a 20 μL
mixture containing 2 μL of the cDNA preparation, 10 μL
2X SYBR Green Premix ExTaq (Takara), and 10 μM
primer on an ABI 7500 Real-Time PCR System (Applied
Biosystems, Grand Island, NY, USA). The PCR conditions
were as follows: 10 min at 95 °C, followed by 40 cycles of
15 s at 95 °C, and 1 min at 60 °C. Each sample was tested
in triplicate. Threshold values were determined for each
sample/primer pair, the average and standard errors were
calculated.
Western blot
The detailed procedure was reported previously [26, 30].
Briefly, cell lysates containing equal amounts of protein
concentration were separated on 10 % SDS polyacryl-
amide gels. Membranes (Millipore, Shanghai, China)
were incubated with antibodies against p38 MAPK, p-
p38 MAPK, FOXO3a and IGFBP1 (1:1000). The mem-
branes were washed and incubated with a secondary
antibody raised against rabbit IgG conjugated to horse-
radish peroxidase (Cell Signaling, Shanghai, China). The
membranes were washed again and transferred to freshly
made ECL solution (Immobilon Western; Millpore,
Shanghai, China), followed by observing the signals
under the Molecular Imager ChemiDoc XRS Gel
Imagine System (BioRad, Hercules, CA, USA) and doc-
umenting the results.
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Xenograft tumors and bioluminescent imaging
In order to explore the effects and mechanisms of UA on
tumor growth in vivo, a xenografted nude mouse model of
HCC cells was established. Animal experiments were ap-
proved by Institutional Animal Care and Use Committee
Animal Care of Guangdong Provincial Hospital of Chinese
Medicine (the Ethics Approval Number 2014012). A total
of 36 female nude mice (eight-week-old) obtained from
Guangdong Provincial Research Center for Laboratory
Animal Medicine (Foshan, Guangdong, China), were
obtained and maintained at the Animal Center of
Guangdong Provincial Hospital of Chinese Medicine in
a specific pathogen-free environment with food and
water provided. HepG2 cells carrying luciferase report
gene (HepG2-Luc, obtained from the Guangzhou Land
Technology Co., Guangzhou, China) (1x106 cells) in
100 μL PBS were injected subcutaneously in nude mice.
Xenografts were allowed to grow for over one week when
the initial measurement was made with calipers and with
bioluminescence imaging (BLI) using the IVIS-200 Im-
aging System (Xenogen Corporation, Berkeley, CA). The
mice were randomly divided into control, low (25 g/kg),
and high doses (50 g/kg) of UA treatment groups, which
based on other studies [34–36]. The UA was given via ga-
vages daily for up to 30 days (n = 12/group).
For bioluminescence imaging (BLI) procedure, the mice
were anesthetized by inhalation of 2 % isoflurane at the end
of experiment. Each set of mice were injected subcutane-
ously (dorsal midline) with 150 mg/kg D-luciferin (Xeno-
gen; PerkinElmer, Waltham, MA, USA) in approximately
200 μL. Imaging and quantification of signals (photons/sec)
were controlled by the acquisition and analysis software
living image (version 1; Xenogen). Tumor volume measure-
ments were calculated using the formula for an oblong
sphere: volume = (width2 × length). The body weights of the
mice were measured once a week. All mice were sacrificed
on 30 days after each treatment using CO2 for euthanasia.
The corresponding xenografted tumors were processed for
detecting the phosphorylation of p38 MAPK, IGFBP1 and
FOXO3a proteins by Western blot.
Statistical analysis
The data are reported as means ± SD of at least three re-
peated experiments in triplicate measures. Differences
between groups were assessed by one-way ANOVA and
significance of difference between particular treatment
groups was analyzed using Dunnett’s multiple comparison
tests (GraphPadPrism5.0 software, LaJolla, CA). The re-
sults were presented relative to the control. Asterisks
showed in the figures indicate significant differences of ex-
perimental groups in comparison with the corresponding
control condition. A probability (p) value of <0.05 was
considered to be significant.
Results
UA inhibited growth of HCC cells in the dose-dependent
fashion
We previously showed that UA suppressed growth of
HepG2 HCC cells [10]. In order to prove if this was
the case in other HCC cell types, we further tested the
effect of UA on the proliferation in other HCC cell
lines. As shown in Fig. 1a, UA inhibited proliferation
of Bel-7402 HCC cells in the dose-dependent manner
with a significant inhibition observed at 25–30 μM
ranges of UA treatment starting at 24 and up to 72 h
as determined by MTT assays. The IC50 was 23.067 μM.
Similar results were also observed in other HCC cell
lines (Fig. 1b). We next performed the cell cycle experi-
ment. As expected, compared with the untreated con-
trol cells, UA significant increased the proportion of
cells at G0/G1 phase (>19 %), while the proportion of
cells at S phases were reduced (Fig. 1c) suggesting that
UA induced cell cycle arrest in G0/G1 phase in Bel-
7402 cells.
UA induced phosphorylation of p38 MAPK
We then explore the signaling pathway that may mediate
the overall response of UA. P38 MAPK signaling path-
way have been shown to be involved in growth, differen-
tiation and progression of cancer [37]. Herein, we
showed that UA increased phosphorylation of p38
MAPK, while it had little effect on total p38 MAPK pro-
tein in the time-dependent manner in Bel-7402 and
HepG2 cells (Fig. 2a–b).
UA induced the expression of protein, mRNA, and
promoter activity of IGFBP1 through p38 MAPK signaling
We next characterized the potential mechanism under-
lying this effect. Studies demonstrated that expression of
IGFBP1 was associated with p38 MAPK signaling and in-
volved in cancer cell growth [38]. In this study, we
found that UA increased the protein expression of
IGFBP1 in a dose-dependent fashion, with a significant
induction seen at 20–30 μM ranges of UA treatment
(Fig. 3a). UA also induced mRNA levels and promoter
activity of IGFBP1 gene as determined by quantitative
real-time PCR (qRT-PCR) and Dual Luminescence
Assays, respectively (Fig. 3b–c). Interestingly, a specific
inhibitor of p38 MAPK (SB203580) abolished the effect
of UA on protein expression and promoter activity of
IGFBP1 in Bel-7402 and HepG2 cells (Fig. 3d–e). Note
that SB203580 inhibited the phosphorylation of p38
MAPK demonstrating the feasibility of this experiment
(Fig. 3d–e). The findings above suggested that induc-
tion of IGFBP1 expression by UA was through the acti-
vation of p38 MAPK signaling pathway.
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UA increased FOXO3a protein expression through
activation of p38 MAPK and expression of IGFBP1
Furthermore, we examined the potential downstream
effectors of IGFBP1. Previous studies demonstrated
the links of IGFBP1 and FOXO3a [39, 40]. For this
reason we explored the role of FOXO3a. We found that
UA also induced protein expression of FOXO3a in the
dose-dependent fashion in Bel-7402 and HepG2 cells
(Fig. 4a). And, this was eliminated in the presence of
SB203580 (Fig. 4b) and in cells silencing of endogenous
Fig. 1 UA inhibited growth of HCC cells in the dose-dependent fashion. a, Bel-7402 cells were treated with increased concentrations of UA for up to 72 h
to examine the cell viability. b, HCC cell lines indicated were treated with UA (25 μM) for 48 h. Afterwards, the cell viability was determined using the MTT
assay as described in the Materials and Methods Section and was expressed as percentage of control in the mean ± SD of three separate
experiments. *Indicates significant difference as compared to the untreated control group (P < 0.05). c, Bel-7402 cells were stimulated with
different concentrations (e.g., 5, 20, 25 μM) of UA for up to 24 h. The cells were collected and processed for analysis of cell cycle distribution.
Cell cycle was analyzed by flow cytometry after propidium iodide (PI) staining, and the percentages of the cell population in each phase (G0/G1, S and
G2/M) of cell cycle were analyzed by Multicycle AV DNA Analysis Software. Data are expressed as a percentage of total cells. Values are given as the
mean ± SD, from 3 independent experiments performed in triplicate. *Represents P < 0.05 versus control group
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IGFBP1 gene using small interfering RNAs (siRNAs)
(Fig. 4c). These results indicated the roles of p38
MAPK activation and expression of IGFBP1 in this
process.
Silencing of FOXO3a overcame UA-inhibited cell growth
and exogenous expressed FOXO3a enhanced UA-induced
phosphorylation of p38 MAPK through IGFBP1
In order to understand the potential role of FOXO3a,
we had knockdown FOXO3a gene using siRNA
method. As shown in Fig. 5a–b, silencing of FOXO3a
had no effect on UA-induced IGFBP1 protein expres-
sion (A); however, it abolished the inhibitory effect
of UA on cell growth in Bel-7402 and HepG2 cells
(B). Moreover, we found that exogenous expressed
FOXO3a enhanced UA-induced phosphorylation of
p38 MAPK, but had little effect on expression of
IGFBP1 protein (Fig. 5c–d). Intriguingly, the feedback
regulation of p38 MAPK by FOXO3a was eliminated
in cells silencing of endogenous IGFBP1 gene (Fig. 5e).
Together, these findings above implied the upstream
role of IGFBP1, and the expression of IGFBP1 was
required for the complicated feedback regulation
loops of p38 MAPK by FOXO3a, which resulted in
the overall effects of UA in this process.
Overexpression of IGFBP1 enhanced the effect of UA on
FOXO3a expression and phosphorylation of p38 MAPK,
and restored UA-inhibited growth in cells silencing of
endogenous IGFBP1 gene
We further identified the role of IGFBP1, and the potential
interactions between IGFBP1 and FOXO3. As expected, we
showed that silencing of IGFBP1 overcame UA-inhibited
cell growth in Bel-7402 and HepG2 cells (Fig. 6a). On the
contrary, exogenous expressed IGFBP1 transfected into the
cells showed to enhance UA-induced FOXO3a protein ex-
pression (Fig. 6b) and strengthened the UA-induced phos-
phorylation of p38 MAPK (Fig. 6c). More importantly, we
further demonstrated that exogenous expression of IGFBP1
restored UA-inhibited growth in Bel-7402 and HepG2 cells
in which endogenous IGFBP1 gene was previously si-
lenced (Fig. 6d). Together, these findings suggested the po-
tential interplay between the tumor suppressors IGFBP1
and FOXO3, and the feedback regulatory axis, resulting in
Fig. 2 UA induced phosphorylation of p38 MAPK. a-b, Bel-7402 (a) and HepG2 (b) cells were exposed to UA (25 μM) for 24 h, followed by measuring
the phosphorylation and protein expression of p38 MAPK by Western blot. The bar graphs represent the mean ± SD of p-p38 MAPK/GAPDH of three
independent experiments. *Indicates significant difference as compared to the zero time group (P < 0.05)
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reciprocal pathways that mediated the overall response
of UA in HCC cells. These results also confirmed the
crucial role of modulation of IGFBP1 gene expression
in this process.
In vivo anti-tumor efficacy of UA in subcutaneous HCC
tumor-bearing nude mice model
We also tested the effect of UA in HCC tumor growth in
nude mouse xenografted cancer model. We found that,
compared to the control, the UA-treated mice (50 mg/kg)
showed a significant growth-inhibitory effect as assessed
by the Xenogen IVIS200 System (Fig. 7a). In addition, we
noticed a significant reduction of the tumor weight and
sizes as compared to the control (Fig. 7b–c). By Western
blot, fresh tumors harvested from the aforementioned
experiment showed that high dose of UA (50 mg/kg)
efficiently increased phosphorylation of p38 MAPK and
protein expressions of IGFBP1 and FOXO3a as compared
to that in the control group (Fig. 7d).
Discussion
Chinese herbal medicines and its components have
drawn a great attention for their potential impact in the
treatment of many cancer types. Increasing numbers of
studies demonstrated that ursolic acid, a pentacyclic tri-
terpenoid found in medicinal herbs and fruits, inhibited
the proliferation and induced the apoptosis in several
types of cancers including HCC cells. We previously
showed that UA inhibited growth and induced apop-
tosis of HepG2 HCC cells through AMPKα-mediated
inhibition of Sp1; this in turn results in inhibition of





Fig. 3 UA induced the protein, mRNA expression, and promoter activity of IGFBP1, which were blocked by SB203580. a-b, HepG2 and Bel-7402
cells were exposed to increased concentrations of UA or UA (25 μM) for 24 h. Afterwards, the expression of IGFBP1 protein (a) and mRNA (b) were
detected by Western blot and qRT-PCR methods as described in the Materials and Methods section. *Indicates significant difference as compared to
the untreated control group (P < 0.05) c, Bel-7402 and HepG2 cells were tranfected with wild type human IGFBP1 promoter reporter construct ligated
to luciferase reporter gene and internal control secreted alkaline phosphatase (SEAP) for 24 h, followed by treating with UA (25 μM) for an additional
24 h. Afterwards, the IGFBP1 promoter activity were detected by the Secrete-Pair Dual Luminescence Assay Kit. d, HepG2 and Bel-7402 cells were
treated with SB203580 (10 μM) for 2 h before exposure of the cells to UA (25 μM) for an additional 24 h. Afterwards, the expression of IGFBP1 protein
and phosphorylation of p38 MAPK were detected by Western blot. The bars represent the mean ± SD of at least three independent experiments for
each condition. *Indicates significant difference as compared to the untreated control group (P < 0.05); **Indicates significance of combination
treatment as compared with UA alone (P < 0.05). e, Cellular protein was isolated from Bel-7402 and HepG2 cells cultured for 2 h in the presence or
absence of SB203580 (10 μM) before transfection with control or above IGFBP1 constructs and exposing the cells to UA (25 μM) for an additional 24 h.
Afterwards, the IGFBP1 promoter activity were detected by the Secrete-Pair Dual Luminescence Assay Kit. The bar graphs represent the mean ± SD of
three independent experiments. *Indicates significant difference as compared to the untreated control group (P < 0.05); **Indicates significance of
combination treatment as compared with UA alone (P < 0.05)
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explored the potential mechanism by which UA con-
trols HCC cell growth. To this end, we showed that UA
inhibited growth of HCC cells through p38 MAPK-
mediated induction expression of transcription factor
IGFBP1 and FOXO3a in reciprocal interacted fashion.
UA was found to inhibit growth in multiple HCC cell
lines in the current study confirming the tumor sup-
pressing properties of this agent in HCC cells. We
did not observe the time-dependent effects of cell
growth inhibition by UA and the reasons remained un-
clear. Whether longer time treatment (>72 h) showed
significant changes needs to be determined. On the
other hand, the possible desensitization of prolonged ex-
posure of UA to the cells may also be responsible for this
occurrence, which required to be confirmed. In our study,
compared to the untreated control cells, there was actually
19 % more G0/G1 phase cell arrest by UA treatment. We
believed that this may explain the significant inhibition of
cell growth by UA, while the possible UA-induced apop-
tosis of HCC cells may also occurred, which required to
be tested further. It was possible that the inhibition of pro-
liferation could be in part a consequence of increased cell
apoptosis. In addition, we demonstrated that UA inhibited
growth of HCC cells through not only AMPKα but
also p38 MAPK indicating that activation of these
two signaling pathways may be required for UA in-
duced HCC growth inhibition [10]. These pathways
reported to be associated with the anti-cancer effects
were also found in other studies suggesting the com-
mon signaling network that mediated the anti-tumor
responses of UA [10, 41–43]. Moreover, regulation of
FOXO3a and IGFBP1 through p38 MAPK signaling
pathway haven been shown in other studies [44, 45].
Of note, inactivation of p38 was also reported to be
involved in the FOXO3a activation and expression
[46]. Thus, the true role of AMPKα and p38 MAPK
signaling in modulating the FOXO3a and/or IGFBP1
expressions required to be determined.
Moreover, our data supported crucial function of IGFBP1
in the current study. Increasing evidence suggested an
BA
C
Fig. 4 UA increased FOXO3a protein expression through activation of p38 MAPK and expression of IGFBP1. a, Bel-7402 and HepG2 cells were
exposed to increased concentrations of UA for 24 h. Afterwards, the expression of FOXO3a protein was detected by Western blot. b, Bel-7402
and HepG2 cells were treated with SB203580 (10 μM) for 2 h before exposure of the cells to UA (25 μM) for an additional 24 h. Afterwards, the
expression of FOXO3a protein and phoisphorylation of p38 MAPK were detected by Western blot. c, Bel-7402 and HepG2 cells were transfected with
control or IGFBP1 siRNAs (50 nM each) for 24 h prior to exposure of the cells to UA (25 μM) for an additional 24 h. Afterwards, FOXO3a and
IGFBP1 protein expressions were determined by Western blot, The bars represent the mean ± SD of at least three independent experiments
for each condition. *Indicates significant difference as compared to the untreated control group (P < 0.05); **Indicates significance of combination
treatment as compared with UA alone (P < 0.05)
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important role of IGFBP in the development and progres-
sion of several types of cancers [16–18, 47]. However, the
expression and function of IGFBP1 in HCC development
remains controversial, and little is known about its true role
including diagnostic and prognostic values in HCC. In fact,
paradoxical data have been reported in terms of the
serum level and expression of IGFBP1 in patients with
HCC [21, 22]. One study showed that that IGFBP1 may
function as a tumor suppressor gene by blunting the
IGF axis [21]. Consistent with this, our results implied
that IGFBP1, acted as a tumor suppressor, could be a
potential target in the HCC therapy.
We also demonstrated the involvement of FOXO3a
that mediated the anti-HCC cell growth by UA. As a
potential tumor suppressor, FOXO3a has been associ-
ated with many physiological and pathological processes,
including proliferation, differentiation, cell cycle arrest,
apoptosis and tumorigenesis [23, 24, 48, 49]. Our results
implied that induction of FOXO3a was required in me-
diating the UA-inhibited HCC growth, which confirmed
the tumor suppressor property of this transcription fac-
tor played in this process. This was the first report dem-
onstrating the role of FOXO3a expression involving in
the inhibition of HCC growth by UA, indicating that
multiple potential targets may be involved in the anti-
HCC effects of UA.
Furthermore, our data also implicated in the correl-





Fig. 5 Silencing of FOXO3a overcame UA-induced cell growth inhibition and exogenous expressed FOXO3a enhanced UA-induced phosphorylation
of p38 MAPK through IGFBP1. a, Bel-7402 and HepG2 cells were transfected with control and FOXO3a siRNAs for 24 h before exposing the cells to UA
(25 μM) for an additional 24 h. Afterwards, FOXO3a and IGFBP1 protein expressions were determined by Western blot. b, Bel-7402 and HepG2 cells
were transfected with control or FOXO3a siRNAs (up to 50 nM each) for 24 h prior to exposure of the cells to UA (25 μM) for an additional 24 h.
Afterwards, FOXO3a protein expression and cell viability were determined by Western blot and MTT assays. Insert represents the protein expression of
FOXO3a. c-d, Bel-7402 and HepG2 cells were transfected with control and FOXO3a overexpression vectors for 24 h before exposing the cells
to UA (25 μM) for an additional 2 and 24 h, respectively. Afterwards, the protein levels of FOXO3a and p-p38 MAPK, and IGFBP1 protein expression
were examined by Western blot. e, Bel-7402 and HepG2 cells silenced of IGFBP1 by siRNA previously were transfected with control and
FOXO3a overexpression vector for 24 h before exposing the cells to UA (25 μM) for an additional 2 and 24 h, respectively. Afterwards, IGFBP1,
FOXO3a protein and phosphorylation of p38 MAPK were determined by Western blot. Values in bar graphs were given as the mean ± SD from
three independent experiments performed in triplicate. *Indicates significant difference as compared to the untreated control group (P < 0.05).
**Indicates significant difference from UA treated alone (P < 0.01). #Indicates significant difference as compared to the IGFBP1 siRNA alone
group (P < 0.05)
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IGFBP1 may be upstream of FOXO3a and mediated the
positive feedback regulatory loop of p38 MAPK by
FOXO3a. This contributed to the UA-inhibited HCC
cell growth. The association between FOXO family and
IGFBP1 has been shown in other studies [40, 50, 51].
For example, FOXO3a was found to bind to the
IGFBP1 proximal promoter region and activated pro-
moter activity thereby regulating its functions [40, 50].
Nevertheless, the true mechanism underlying this regu-
lation still remain to be determined. Moreover, we dem-
onstrated a novel feedback regulation of p38 MAPK by
FOXO3a and IGFBP1, and this kinase regulatory loop
may contribute to the overall inhibitory effects of UA on
HCC cell growth. However, the other potential signaling
pathways and up- or downstream mediators involving in
this regulatory axis, and the true correlation between
FOXO3a and IGFBP1 required to be elucidated in the
future studies. Collectively, our findings indicated that
targeting IGFBP1 and FOXO3a may be an alternative
strategy in the treatment of HCC that warrants further
investigation.
More importantly, our in vivo data were consistent
with the findings from that in vitro, confirming the ef-
fect of UA on liver cancer growth inhibition and regula-
tion of IGFBP1, FOXO3a expression, and p38 MAPK
phosphorylation. The doses used for UA in the current
study were similar to other reports demonstrating the
significant effects in inhibiting growth of several cancer
types including HCC [34–36]. Nevertheless, more ex-
periments are needed to further elucidate the important
role and the correlation between IGFBP1 and FOXO3a
in this process using cells stable transfected with
shRNAs or exogenous expressed IGFBP1 and/or





Fig. 6 Overexpression of IGFBP1 enhanced the effect of UA on FOXO3a expression and phosphorylation of p38 MAPK, and restored UA-inhibited
cell growth in cells silencing of endogenous IGFBP1 gene. a, Bel-7402 and HepG2 cells were transfected with control or IGFBP1 siRNAs (50 nM each)
for 24 h prior to exposure of the cells to UA (25 μM) for an additional 24 h. Afterwards, IGFBP1 protein expression and cell viability were determined by
Western blot and MTT assays. b-c, Bel-7402 and HepG2 cells were transfected with control and IGFBP1 overexpression vectors for 24 h before exposing
the cells to UA (25 μM) for an additional 2 and 24 h, respectively. Afterwards, IGFBP1, FOXO3a protein levels and phosphorylation of p38 MAPK
were determined by Western blot. d, Bel-7402 and HepG2 cells silenced of IGFBP1 by siRNA previously were transfected with control and
IGFBP1 overexpression vectors for 24 h before exposing the cells to UA (25 μM) for an additional 24 h. Afterwards, IGFBP1 protein expressions
and cell viability were determined by Western blot and MTT assays. Values in bar graphs were given as the mean ± SD from three independent
experiments performed in triplicate. *Indicates significant difference as compared to the untreated control group (P< 0.05). **Indicates significant difference
from UA treated alone (P< 0.05)
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Conclusion
Overall, our results show that UA inhibits HCC cell pro-
liferation through p38 MAPK-mediated induction of
IGFBP1 gene expression and upregulation of FOXO3a.
The inter-correlation between IGFBP1 and FOXO3a,
and positive feedback regulatory loop of p38 MAPK by
IGFBP1 and FOXO3a resulting in reciprocal pathways,
contribute to the overall effects of UA (Fig. 7e). This in
vitro and in vivo study corroborates a potential novel
mechanism by which UA controls HCC cell growth and
implies that the rational targeting IGFBP1 and FOXO3a
can be potential for therapeutic strategies against HCC.
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Fig. 7 In vivo anti-tumor efficacy of UA in subcutaneous HCC tumor-bearing nude mice. Mice (n = 12/group) were divided to 3 groups [Con (saline),
Low (L, 25 mg/kg) and High doses of UA (H, 50 mg/kg)], and UA was given daily around the 10th day after tumor cells injection by gavages for up to 30
days. a, The xenografts were assessed by in vivobioluminescence imaging at the first and the end of the experiments [on day 1 (D 1) and Day 30 (D 30)].
The tumor growth was monitored by injecting luciferin in the mice followed by measuring bioluminescence using IVIS Imaging System. Imaging and
quantification of signals were controlled by the acquisition and analysis software living image as described in the Materials and Methods
section. Representative images are shown. b and c, The xenografts were harvested on day 30, and the volume and weight of tumors were
measured. d, At the end of the experiments, xenografted tumors in each group were isolated and the tumors lysates were processed for detecting IGFBP1,
FOXO3a protein and phosphorylation of p38 MAPK by Western blot. GAPDH was used as loading control. The bar graphs represented the tumor weight
and volume of mice results as mean ± SD. *Indicates the significant difference from untreated control (p< 0.05). e, The diagram shows that UA inhibits
growth of HCC cells through p38 MAPK-mediated induced expressions of IGFBP1 and FOXO3a. The interactions and correlations between IGFBP1 and
FOXO3a, and the feedback regulatory loop of p38 MAPK by IGFBP1 and FOXO3a resulting in reciprocal pathways, contribute to the overall effects of UA
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